Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder

By Corcos Jacques   Angulo Javier C.   Garely Alan D.   Carlsson Martin   Gong Jason   Guan Zhonghong  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 1059-1065

Informa Healthcare

Access to resources Recommend Favorite

Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms

By Scarpero Harriette   Sand Peter K.   Kelleher Con J.   Berriman Sandra   Bavendam Tamara   Carlsson Martin  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 921-930

Informa Healthcare

Access to resources Recommend Favorite

Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study

By  

NEUROUROLOGY AND URODYNAMICS, Vol. 34, Iss. 5, 2015-06 ,pp. : 438-443

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis

By Millard R. J.   Halaska M.  

Current Medical Research and Opinion, Vol. 22, Iss. 1, 2006-01 ,pp. : 41-48

Informa Healthcare

Access to resources Recommend Favorite

Onset of efficacy of tolterodine extended release in patients with overactive bladder

By Sussman David O.   Kraus Stephen R.   Carlsson Martin   Guan Zhonghong  

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 777-781

Informa Healthcare

Access to resources Recommend Favorite